PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTION

This study is testing a new, long-acting injection called lenacapavir, given just twice a year, to see if it can safely prevent HIV infection in women in the United States. It will compare this injection to a standard daily pill. The main goals are to see how the drug moves throu…

This study is testing a new, long-acting injection called lenacapavir, given just twice a year, to see if it can safely prevent HIV infection. It involves 181 adults in the U.S. who inject drugs and are at high risk for HIV. The main goals are to see how the drug moves through th…

This large Phase 3 study is testing whether a new drug called lenacapavir, given as an injection just twice a year, can safely prevent HIV infection. It enrolled over 3,200 cisgender men, transgender women, transgender men, and nonbinary people aged 16+ who have condomless sex wi…

This study is testing a new long-acting injection called lenacapavir for preventing HIV. It compares how well people stick with getting the shot twice a year versus taking a daily pill. The research will also look at the safety of both methods, how acceptable they are to particip…